Date
- 2024 (29)
- 2023 (48)
- 2022 (26)
- 2021 (102)
- 2020 (61)
- 2019 (127)
- 2018 (41)
- 2017 (23)
- 2016 (26)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (12)
- 2008 (6)
- 2007 (12)
- 2006 (12)
- 2005 (15)
- 2004 (5)
- 2003 (3)
- 2002 (7)
- 2001 (4)
- 2000 (12)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (10)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (23)
Results for
"[search-keyword]"
Sponsor content
677 result(s) found, displaying 81 to 90
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Australian Public Assessment Report (AusPAR)AusPAR for NEXVIAZYME (avalglucosidase alfa) for long-term enzyme replacement therapy for the treatment of Pompe disease.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for NEXVIAZYME avalglucosidase alfa powder for injection100mg/10mL vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for REZUROCK belumosudil 200 mg (as mesilate) film-coated tablets bottle.
-
Prescription medicine decision summaryVerorab (inactivated rabies virus) is approved to treat rabies.
-
Australian Public Assessment Report (AusPAR)AusPAR for LIBTAYO (cemiplimab) for treatment of adult patients with locally advanced and metastatic basal cell carcinoma.
-
Prescription medicine registrationActive ingredients: Rabies virus.
-
Australian Public Assessment Report (AusPAR)New AusPAR for LIBTAYO (cemiplimab) as first-line treatment of adult patients with non-small cell lung cancer.